SEMA-CardioDiab HUNGARY: A Research Study to Understand the Effects of Oral Semaglutide on Blood Sugar Levels, Weight, and Cardiovascular Risk in People With Type 2 Diabetes Patients in Hungary
← catalyst calendarSponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
243actual
Sites
19
Country
Hungary
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-09-30 | actual | When the study began enrolling |
| Primary completion | 2026-05-05 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-05-05 | actual | The whole study's end, after follow-up |
| First posted | 2024-02-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Type 2 Diabetes
Intervention
- Drug: Oral Semaglutide
Primary outcome
what the primary-completion date above is the date OFGlycated haemoglobin (HbA1c ) reduction greater than or equal to (≥) 0.5%-point and body weight reduction ≥ 5%
measured From Baseline to end of study (week 32)
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed